1669-85-8

Basic information

• Product Name: N-(2-CHLOROETHYL)-N-METHYLANILINE
• Synonyms: N-(2-CHLOROETHYL)-N-METHYLANILINE;N-Methyl-N-(2-chloroethyl)aniline
• CAS NO: 1669-85-8
• Molecular Formula: C₉H₁₂ClN
• Molecular Weight: 169.65128
• Mol File: 1669-85-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 241.5°Cat760mmHg
• Flash Point: 99.9°C
• Appearance: /
• Density: 1.092g/cm³
• Vapor Pressure: 0.0357mmHg at 25°C
• Refractive Index: 1.557
• CAS DataBase Reference: N-(2-CHLOROETHYL)-N-METHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-CHLOROETHYL)-N-METHYLANILINE(1669-85-8)
• EPA Substance Registry System: N-(2-CHLOROETHYL)-N-METHYLANILINE(1669-85-8)

Safety Data

• Hazardous Substances Data: 1669-85-8(Hazardous Substances Data)

Usage

General Description

N-(2-chloroethyl)-N-methylaniline is a chemical compound with the molecular formula C8H10ClN. It is a colorless to pale yellow liquid that is used in the synthesis of dyes and pharmaceuticals. N-(2-CHLOROETHYL)-N-METHYLANILINE is classified as an aromatic amine and contains a chlorine atom and a methyl group attached to the nitrogen atom. It is important to handle this chemical with care, as it is a potential carcinogen and can cause irritation to the skin, eyes, and respiratory system. Additionally, it may be harmful if swallowed, inhaled, or in contact with the skin. Due to its potential hazards, proper safety precautions and protective equipment should be used when working with this compound.

InChI:InChI=1/C9H12ClN/c1-11(8-7-10)9-5-3-2-4-6-9/h2-6H,7-8H2,1H3

Upstream product

• 7647-01-0 hydrogenchloride 
• 51905-47-6 N-Methyl,N-{(2-bromo)-1-ethyl}aniline 
• 80-41-1 2-chloroethyl tosylate 
• 100-61-8 N-methylaniline 
• 79-11-8 chloroacetic acid 
• 107-04-0 1-Bromo-2-chloroethane 
• 93-90-3 N-(2-hydroxyethyl)-N-methylaminobenzene 

Downstream Products

• 20322-87-6 2-(methyl(phenyl)amino)ethyl benzoate 
• 51905-47-6 N-Methyl,N-{(2-bromo)-1-ethyl}aniline 
• 5185-74-0 N-(2-chloro-ethyl)-N-methyl-4-nitroso-aniline 
• 74474-29-6 N,N-diethyl-N'-methyl-N'-phenyl-ethylenediamine 
• 94-31-5 N-(2-chloroethyl)-N-methyl-4-aminobenzaldehyde 
• 1431659-35-6 4-(2-(methyl(phenyl)amino)ethoxy)phenol 
• 5185-72-8 N-Methyl-N-(2-chloroethyl)-p-arsanilic Acid 
• 62783-77-1 2-{4-[(2-chloro-ethyl)-methyl-amino]-trans-styryl}-1,3,3-trimethyl-3H-indolium; iodide 
• 76578-89-7 2-(4-formyl-N-methyl-anilino)-ethanesulfonic acid 
• 73268-78-7 3t-{4-[methyl-(2-chloro-ethyl)-amino]-phenyl}-2-cyano-acrylic acid ethyl ester 
• 1201-91-8 4-(N-methyl-N-hydroxyethylamino)benzaldehyde 
• 871885-00-6 1-(N-methyl-4-nitroso-anilino)-2-(4-nitro-benzoyloxy)-ethane 
• 861339-00-6 4-amino-benzoic acid-[2-(4-amino-N-methyl-anilino)-ethyl ester] 

Relevant articles and documents

Ru-Catalyzed Switchable N-Hydroxyethylation and N-Acetonylation with Crude Glycerol

Highly efficient Ru-catalyzed selective C?C or C?O bond cleavage of polyols (e.g., crude glycerol) for N-hydroxyethylation or N-acetonylation of amines was achieved through the hydrogen-borrowing approach. A variety of amines were transformed to the desired amino alcohols/ketones in moderate-to-excellent yields, opening up new avenues for generation of oxygenated pharmaceuticals and fine chemicals from renewable raw materials. The use of new redox-active catalysts containing bisphosphine/thienylmethylamine ligands allows this hydrogen-borrowing system to be operated selectively under both basic and acidic conditions.

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

This study explores the possible use of reactive oxygen-activated DNA modifying agents against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progenitor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this novel type of agent may be useful against AML.

Synthesis and pharmacological activity of some new pyridazinones

The synthesis of a series of piperazinyl-pyridazinones is reported. The blocking activity of these compounds was determined on the pre- and postsynaptic α-adrenoreceptors of isolated rat vas deferens. For compounds 7, 17 and 18, the hypotensive activity w